DAY ONE BIOPHARMACEUTICALS I's ticker is DAWN and the CUSIP is 23954D109. A total of 33 filers reported holding DAY ONE BIOPHARMACEUTICALS I in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $15,582,802 | +2.8% | 1,269,992 | 0.0% | 0.34% | +5.9% |
| Q2 2023 | $15,163,704 | -26.9% | 1,269,992 | +31.7% | 0.32% | -24.5% |
| Q4 2022 | $20,745,990 | +0.4% | 964,033 | -6.6% | 0.43% | +4.4% |
| Q3 2022 | $20,671,000 | -67.1% | 1,032,000 | -70.6% | 0.41% | -68.3% |
| Q2 2022 | $62,867,000 | +203.7% | 3,512,123 | +68.3% | 1.30% | +180.1% |
| Q1 2022 | $20,698,000 | -44.2% | 2,086,449 | -5.3% | 0.46% | -40.5% |
| Q4 2021 | $37,113,000 | -8.6% | 2,202,533 | +28.7% | 0.78% | -1.8% |
| Q3 2021 | $40,596,000 | +117.7% | 1,710,730 | +108.9% | 0.79% | +139.3% |
| Q2 2021 | $18,648,000 | – | 818,980 | – | 0.33% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Canaan Partners XI LLC | 9,663,645 | $95,863,000 | 39.92% |
| Atlas Venture Life Science Advisors, LLC | 8,201,638 | $81,360,000 | 10.29% |
| RA Capital Management | 6,060,090 | $60,116,000 | 1.31% |
| Boxer Capital, LLC | 1,189,943 | $11,804,000 | 0.61% |
| Samsara BioCapital, LLC | 202,500 | $2,009,000 | 0.51% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,086,449 | $20,698,000 | 0.46% |
| BVF INC/IL | 809,282 | $8,028,000 | 0.32% |
| Summit Rock Advisors, LP | 33,125 | $329,000 | 0.20% |
| Perceptive Advisors | 556,047 | $5,516,000 | 0.11% |
| Nan Fung Group Holdings Ltd | 11,445 | $114,000 | 0.05% |